Journal article icon

Journal article

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M

Abstract:

The use of viral vectors in heterologous prime-boost regimens to induce potent T cell responses in addition to humoral immunity is a promising vaccination strategy in the fight against malaria. We conducted an open-label, first-in-human, controlled Phase I study evaluating the safety and immunogenicity of Matrix-M adjuvanted vaccination with a chimpanzee adenovirus serotype 63 (ChAd63) prime followed by a modified vaccinia Ankara (MVA) boost eight weeks later, both encoding the malaria ME-TRA...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/j.vaccine.2017.09.028

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More from this funder
Name:
National Institute of Health Research
Grant:
Oxford Biomedical Centre vaccines theme
Publisher:
Elsevier
Journal:
Vaccine More from this journal
Volume:
35
Issue:
45
Pages:
6208-6217
Publication date:
2017-09-21
Acceptance date:
2017-09-07
DOI:
ISSN:
0264-410X
Keywords:
Pubs id:
pubs:726031
UUID:
uuid:acb1b159-7dd8-4fbf-b7f2-ef9282b74239
Local pid:
pubs:726031
Source identifiers:
726031
Deposit date:
2017-09-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP